KAZIA THERAPEUTICS LIMITED (KZIA) at GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - KAZIA THERAPEUTICS LTD

Financial Performance:

• The company holds approximately $80 million in cash following recent financing, providing a runway extending well into 2031.
• As a clinical-stage biotech, the company currently reports no revenue; financial focus is on capital management to support multi-year clinical execution.

Guidance and Future Outlook:

• 2027 is designated as a year of clinical execution and data generation across all major programs.
• Triple Negative Breast Cancer (TNBC): Full enrollment (36 patients) for the Phase 1B Stage IV trial expected by summer 2027, with meaningful data updates anticipated throughout 2027.
• HR-Positive Breast Cancer: First patient enrollment expected by end of 2027 for a 78-patient study; full enrollment expected by end of 2027.
• Colorectal Cancer (CRC): Phase 2 study enrollment (approx. 90 patients) expected to be completed by end of 2027, with trial launch in Q1 2027.
• R&D Platform: IND-enabling activities for DB1 (chromatin-focused degrader) and clinical initiation for PDL1 degrader (NDEL2) targeted before end of 2027; R&D day updates scheduled for early December 2024.

Business Segments and Product Lines:

• Lead Asset (Paxalisib): An oral, once-daily dual PI3K/mTOR inhibitor with blood-brain barrier penetrance. Currently in Phase 1B for Stage IV TNBC (in combination with pembrolizumab/chemo).
• Mechanism of Action (Novelty): Distinct from peers due to ability to cross the nuclear membrane, targeting a non-canonical PI3K pathway to induce epigenetic reprogramming of cancer stem cells and terminally exhausted CD8 T cells.
• Secondary Asset (EVT801): A VEGFR3-specific protein degrader; Phase 1 completed.
• R&D Platforms: Includes DB1 (bicyclic peptide chromatin degrader) and NDEL2 (nuclear-based PD-L1 protein degrader).
• Pipeline Expansion: Plans to expand Paxalisib indications to HR-positive breast cancer (Hormone Receptor positive), colorectal cancer (specifically PMMR), and early-stage TNBC (adjuvant setting).

Market and Competitive Landscape:

• Differentiation: Management positions Paxalisib as distinct from "fast follower" PI3K inhibitors by addressing recurrence via immune reprogramming and nuclear targeting, rather than solely traditional kinase inhibition.
• Colorectal Market: Targets the ~80-85% of metastatic CRC that is POLE/PMMR (microsatellite stable), a population where checkpoint inhibitors have historically failed.
• TNBC Market: Aims to benefit patients ineligible for checkpoint inhibitors (CPS score 1-10) and those with residual disease in earlier stages.
• Competition: While other dual PI3K/mTOR inhibitors exist (e.g., verbal), Paxalisib differentiates via unique pharmacokinetics allowing nuclear entry.

Risks and Challenges:

• Clinical Execution: Reliance on successful enrollment timelines and the translation of preclinical biomarker data into clinical efficacy (PFS/OS).
• Toxicity Management: Mitigating historical class effects of PI3K/mTOR inhibitors (hyperglycemia, stomatitis, bone marrow dyscrasias) using a unique low-dose daily regimen; while early data suggests safety, long-term tolerability remains a variable.
• Competitive Pressure: The crowded landscape of breast and colorectal cancer therapies, particularly with the emergence of ADCs.

Management Commentary and Tone:

• Tone: Highly confident and optimistic, emphasizing a "bench-to-bedside" translation of unique scientific findings.
• Strategy: Management stresses moving beyond "me-too" drugs by leveraging Paxalisib's specific nuclear targeting capabilities to address unmet needs in recurrence and immunotherapy resistance.
• Capital Strategy: Highlighting the strong cash position ($80M+) as a strategic advantage allowing for sustained execution without near-term dilution pressure.

Analyst Questions and Answers:

• Safety/Tolerability: Confirmed that the low-dose daily regimen minimizes on-target toxicities (stomatitis, hyperglycemia) compared to traditional dosing, supported by data from 580+ patients dosed previously in neuro-oncology.
• Biomarkers: Confirmed that in the first six TNBC patients, Paxalisib reduced circulating tumor cells and reprogrammed (rather than killed) terminally exhausted CD8 T cells.
• Indication Eligibility: Protocol amended to include patients with lower CPS scores (1-10) who are ineligible for standard checkpoint inhibitor monotherapy.
• Data Readouts: Clarified that the company prefers meaningful data updates (e.g., 10-12 patient cohorts) over incremental "one or two" patient updates.

Other Key Points:

• Historical Context: Paxalisib was originally discovered by Genentech for glioblastoma (neuro-oncology) but the company pivoted to broader solid tumors after identifying epigenetic effects in preclinical models.
• Upcoming Catalysts: R&D Day scheduled for December 2nd to present data on protein degrader platforms; updates expected at major oncology meetings (SABCS, etc.) regarding benchmarking data.
• Target Patient Population: Specific focus on "recurrence" and "progression" avoidance in high-risk early-stage and metastatic settings through immune system reactivation.